Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
IVIG for Severe Refractory CDAD
NCT00177970Phase 4Terminated
- Sponsor
- University of Pittsburgh
- Start
- Oct 2003
- Primary completion
- Apr 2008
- Modality
- Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 4, randomised, double-blind trial in Clostridium difficile infection (CDI) comparing IVIG with Placebo (2 arms). Primary endpoints: Normalization of WBC's and Decrease of Number of Loose Stools to <3 Per Day Following Treatment. Started Oct 2003; status: terminated.
02
Drugs
intravenous immunoglobulin G
03
Conditions
Clostridium difficile infection (CDI)
Beyond the preview
Go deeper on NCT00177970.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00177970.